144 related articles for article (PubMed ID: 26881596)
1. Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma.
Gang G; Hongkai Y; Xu Z
J Cancer Res Ther; 2015; 11(4):1026. PubMed ID: 26881596
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Giorgio A; Merola MG; Montesarchio L; Merola F; Santoro B; Coppola C; Gatti P; Amendola F; DI Sarno A; Calvanese A; Matteucci P; Giorgio V
Anticancer Res; 2016 Nov; 36(11):6179-6183. PubMed ID: 27793949
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Park JG; Park SY; Lee HW
World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
8. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Liang HY; Lu LG; Hu BS; Li Y; Shao PJ
Chin Med J (Engl); 2013 Nov; 126(22):4270-6. PubMed ID: 24238511
[TBL] [Abstract][Full Text] [Related]
9. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
10. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
11. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
Chen L; Sun J; Yang X
Cancer Lett; 2016 Jan; 370(1):78-84. PubMed ID: 26472630
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma.
Yang T; Zhang H; Shen YN; Wu MC; Shen F; Schwartz M
Am J Gastroenterol; 2015 Apr; 110(4):595. PubMed ID: 25853196
[No Abstract] [Full Text] [Related]
15. Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: a glimmer of light after the storm trial?
Facciorusso A; Muscatiello N; Di Leo A; Barone M
Am J Gastroenterol; 2015 May; 110(5):770-1. PubMed ID: 25942304
[No Abstract] [Full Text] [Related]
16. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
17. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
Shinoda M; Kishida N; Itano O; Ei S; Ueno A; Kitago M; Abe Y; Hibi T; Yagi H; Masugi Y; Tanabe M; Aiura K; Sakamaoto M; Tanimoto A; Kitagawa Y
World J Surg Oncol; 2015 Apr; 13():144. PubMed ID: 25889667
[TBL] [Abstract][Full Text] [Related]
18. [Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
Kitade H; Yanagida H; Yokoigawa N; Yamada M; Hijikawa T; Kaibori M; Matsui K; Ishizaki M; Yoshioka K; Kon M
Gan To Kagaku Ryoho; 2015 Jul; 42(7):863-5. PubMed ID: 26197751
[TBL] [Abstract][Full Text] [Related]
19. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.
Cui HZ; Dai GH; Shi Y; Chen L
Hepatogastroenterology; 2013; 60(122):305-10. PubMed ID: 23574656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]